Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    Sareum Holdings

    MCap

    GBP28m

    Last close

    GBP0.27

    ▲ 6.25 (30.49%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

IRLAB Therapeutics AB: Edison Open House Healthcare 2022

IRLAB Therapeutics AB: Edison Open House Healthcare 2022

IRLAB Therapeutics — 5 videos in collection

More on this equity

IRLAB Therapeutics AB is dedicated to the discovery and development of new drugs for treatment of Parkinson’s disease and other life-altering diseases that affect the central nervous system (CNS). IRLAB strive to transform the everyday life for patients who lack effective treatment options.

• Tell us about the company, its key assets and the particular areas of focus.
• What is IRLAB’s proprietary ISP platform, which leads to these discoveries?
• Tell us about some of the company’s assets.
• Tell us more about the successful deal to out-license your lead asset Mesdopetam to Ipsen in summer 2021.
• At what stage is pirepemat, your next most advanced Parkinson’s asset, in its development timeline?
• Are the other developments in your pipeline also assets focusing on the neglected effects of Parkinson’s disease?
• Which milestones should investors look out for in the coming year?

< Previous
Next >

You may also be interested in these:

Healthcare

IRLAB Therapeutics – executive interview

Healthcare

IRLAB Therapeutics – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free